Nasopharyngeal Carcinoma Treatment Global Market Report 2025
상품코드:1825470
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
세계의 비인두암 치료 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년까지 16억 5,000만 달러로 성장해 CAGR은 6.6%로 예상됩니다. 예측 기간의 성장은 새로운 표적 치료, 개인화된 의료 접근법, 치료 접근의 세계 확장, 임상시험의 성공, 조기 발견에 대한 지속적인 주력에 기인합니다. 예측기간의 주요 동향으로는 병용요법의 도입, 지지요법과 QOL 중시, 치료계획에서의 인공지능(AI) 통합, 임상시험과 연구 이니셔티브의 확대, 조기발견을 위한 영상기술의 강화 등이 있습니다.
향후 5년간의 성장률 6.6%라는 예측은 이 시장의 지난 예측으로부터 0.2% 소폭 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세 인상은 독일과 일본에서 수입되는 세기조절 방사선 치료 컴포넌트와 엡스타인바 바이러스(EBV) 표적 면역요법의 비용을 밀어 올리고, 이 희소암의 치료비를 악화시키기 때문에 종양 센터에 있어서 부담이 될 가능성이 높습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 넓어질 것으로 보입니다.
비인두암 치료 시장은 담배 소비 증가로 성장이 촉진될 것으로 예측됩니다. 담배는 담배 잎을 건조시킨 것으로, 일반적으로 흡연이나 씹기에 사용되며, 다양한 담배 제품의 주요 성분이 되고 있습니다. 담배의 사용이 늘어나면 비인두암을 발병할 위험이 높아져 수술, 방사선요법, 화학요법, 표적요법 등의 효과적인 치료 옵션이 필요합니다. 주목할만한 것은 캐나다 통계국의 보고에 따르면 2023년 7월 캐나다에서 담배 생산량은 6월에 비해 2.2% 급증하고 담배 판매량도 2.6% 증가했으며 6월에는 14억 병에 달했습니다. 따라서 담배소비량 증가가 비인두암 치료 시장 확대를 견인하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 태와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 비인두암 치료 시장 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 비인두암 치료 시장 : 성장률 분석
세계의 비인두암 치료 시장 실적 : 규모와 성장, 2019-2024년
세계의 비인두암 치료 시장 예측 : 규모와 성장, 2024-2029년, 2034년
세계의 비인두암 치료 시장 : 총 시장 규모(TAM)
제6장 시장 세분화
세계의 비인두암 치료 시장 : 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
비각화 미분화 암
비각화 분화암
각화 편평상피암
세계의 비인두암 치료 시장 : 의약품별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
엘렌스
탁소테일
블레오마이신
메토트렉사트
세계의 비인두암 치료 시장 : 치료법별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
화학요법
면역요법
방사선치료
기타 치료법
세계의 비인두암 치료 시장 : 유통 채널별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
병원 약국
소매 약국
온라인 약국
세계의 비인두암 치료 시장 : 비각화성 미분화암 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
저분화형
고분화형
세계의 비인두암 치료 시장 : 비각화 분화암 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
분화형
세계의 비인두암 치료 시장 : 각화 편평상피암 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
각질화 유형
제7장 지역별/국가별 분석
세계의 비인두암 치료 시장 : 지역별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
세계의 비인두암 치료 시장 : 국가별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
비인두암 치료 시장 : 경쟁 구도
비인두암 치료 시장 : 기업 프로파일
Sanofi SA : 개요, 제품 및 서비스, 전략 및 재무 분석
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Merck & Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Novartis AG : 개요, 제품 및 서비스, 전략 및 재무 분석
Bristol Myers Squibb Company : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
AstraZeneca plc
Eli Lilly and Company
Amgen Inc.
CH Boehringer Sohn AG & Co. KG.
Regeneron Pharmaceuticals Inc.
Astellas Pharma Inc.
Eisai Co. Ltd.
Incyte Corporation
Ipsen SA
Dr. Reddys Laboratories Ltd.
Hikma Pharmaceuticals plc
Exelixis Inc.
BeiGene Ltd
Taiho Pharmaceutical Co. Ltd.
Simcere Pharmaceutical Group
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
비인두암 치료 시장(2029년) : 새로운 기회를 제공하는 국가
비인두암 치료 시장(2029년) : 새로운 기회를 제공하는 부문
비인두암 치료 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
JHS
영문 목차
영문목차
Nasopharyngeal carcinoma (NPC) is a type of cancer that originates in the nasopharynx, the upper part of the throat located behind the nose. The treatment of nasopharyngeal carcinoma involves various medical interventions and therapies aimed at managing and combating cancerous growth in the nasopharynx, with goals such as achieving remission, managing symptoms, and improving the overall well-being of the patient.
The main types of nasopharyngeal carcinoma include non-keratinizing undifferentiated carcinoma, non-keratinizing differentiated carcinoma, and keratinizing squamous cell carcinoma. Non-keratinizing undifferentiated carcinoma is characterized by the absence of keratin, a protein typically found in the outer layers of the skin. Treatment for this type of carcinoma typically involves a combination of radiation therapy and chemotherapy. Chemotherapy drugs such as ellence, taxotere, bleomycin, and methotrexate are employed in various treatment modalities, including chemotherapy, immunotherapy, radiation therapy, and others. These drugs are distributed through hospital pharmacies, retail pharmacies, and online pharmacy channels.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The nasopharyngeal carcinoma treatment market research report is one of a series of new reports from The Business Research Company that provides nasopharyngeal carcinoma treatment market statistics, including nasopharyngeal carcinoma treatment industry global market size, regional shares, competitors with a nasopharyngeal carcinoma treatment market share, detailed nasopharyngeal carcinoma treatment market segments, market trends and opportunities, and any further data you may need to thrive in the nasopharyngeal carcinoma treatment industry. This nasopharyngeal carcinoma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The nasopharyngeal carcinoma treatment market size has grown strongly in recent years. It will grow from $1.21 billion in 2024 to $1.27 billion in 2025 at a compound annual growth rate (CAGR) of 5.1%. The growth in the historic period can be attributed to high prevalence in endemic regions, advancements in radiation therapy, improved diagnostic methods, awareness and screening programs, collaborative research initiatives.
The nasopharyngeal carcinoma treatment market size is expected to see strong growth in the next few years. It will grow to $1.65 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to emerging targeted therapies, personalized medicine approaches, global expansion of treatment access, clinical trial successes, continued focus on early detection. Major trends in the forecast period include implementation of combination therapies, focus on supportive care and quality of life, integration of artificial intelligence (AI) in treatment planning, expansion of clinical trials and research initiatives, enhanced imaging technologies for early detection.
The forecast of 6.6% growth over the next five years reflects a modest reduction of 0.2% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden oncology centers by driving up costs of intensity-modulated radiation therapy components and Epstein-Barr virus(EBV)-targeted immunotherapies imported from Germany and Japan, exacerbating treatment expenses for this rare cancer. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The nasopharyngeal carcinoma treatment market is expected to witness growth propelled by the rise in tobacco consumption. Tobacco, derived from dried leaves of the tobacco plant, is commonly used for smoking or chewing and is a key component in various tobacco products. Increased tobacco use elevates the risk of developing nasopharyngeal carcinoma, necessitating effective treatment options such as surgery, radiation therapy, chemotherapy, and targeted therapies. Notably, Statistics Canada reported a 2.2% surge in cigarette production in Canada in July 2023 compared to June, coupled with a 2.6% increase in cigarette sales, reaching 1.4 billion units in June. Hence, the escalating tobacco consumption drives the expansion of the nasopharyngeal carcinoma treatment market.
The nasopharyngeal carcinoma treatment market is projected to grow due to an upsurge in Epstein-Barr virus (EBV) infections. EBV, a highly contagious infection belonging to the herpesvirus family, is closely linked to Nasopharyngeal Carcinoma (NPC). The virus spreads primarily through bodily fluids, notably saliva, and is strongly associated with NPC development. The National Library of Medicine reported a staggering 95% global adult population exposure to EBV in August 2023. Moreover, in the United States, EBV prevalence among children and adolescents varies, with infection rates around 54% in certain age groups and peaking at approximately 82.9% among adolescents aged 18 to 19. Consequently, the escalating incidence of EBV infections drives growth in the nasopharyngeal carcinoma treatment market.
Major players in the nasopharyngeal carcinoma treatment market are concentrating on developing advanced technological solutions, such as Loqtorzi, to meet various critical industry needs. Loqtorzi is an oral medication for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) that targets tumor growth while minimizing side effects. It can be utilized alongside other therapies to boost effectiveness. For example, in January 2024, Coherus BioSciences, a US-based biopharmaceutical firm, launched LOQTORZI (toripalimab-tpzi), the first FDA-approved treatment for nasopharyngeal carcinoma (NPC) applicable across all lines of therapy. This anti-PD-1 monoclonal antibody is indicated for use in conjunction with chemotherapy for first-line treatment and as a standalone therapy for patients who have progressed after platinum-based chemotherapy. Clinical trials have demonstrated that LOQTORZI significantly enhances progression-free survival and overall survival. The drug is currently available through select specialty distributors, and Coherus is committed to improving patient access and education through initiatives like NPCFacts.com, marking a notable advancement in treatment options for this aggressive cancer type.
In April 2024, Genmab A/S, a biotechnology company based in Denmark, acquired ProfoundBio Inc. for $1.8 billion. This acquisition aims to significantly enhance Genmab's oncology portfolio by providing access to next-generation antibody-drug conjugates (ADCs) and proprietary technology platforms. ProfoundBio Inc. is a US-based clinical-stage biotechnology firm that develops antibody-based therapeutics for cancer patients.
Major companies operating in the nasopharyngeal carcinoma treatment market report are Sanofi S.A., Pfizer Inc., Merck & Co. Inc., Novartis AG, Bristol Myers Squibb Company, AstraZeneca PLC, Eli Lilly and Company, Amgen Inc., C.H. Boehringer Sohn AG & Co. KG., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Eisai Co. Ltd., Incyte Corporation, Ipsen S.A., Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Exelixis Inc., BeiGene Ltd., Taiho Pharmaceutical Co. Ltd., Simcere Pharmaceutical Group, Daiichi Sankyo Company Limited, BioDiem Ltd., Coherus BioSciences Inc., Shanghai Junshi Bioscience Co Ltd., Genentech Inc., Helsinn Group, Cyclacel Pharmaceuticals Inc., Advenchen Laboratories LLC.
North America was the largest region in the nasopharyngeal carcinoma treatment market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nasopharyngeal carcinoma treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the nasopharyngeal carcinoma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The nasopharyngeal carcinoma treatment market consists of revenues earned by entities by providing proton therapy, brachytherapy, external-beam radiation therapy services. The market value includes the value of related goods sold by the service provider or included within the service offering. The nasopharyngeal carcinoma treatment market also includes sales of loqtorzi, cetuximab, gemcitabine, and cisplatin used in nasopharyngeal carcinoma treatment. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Nasopharyngeal Carcinoma Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on nasopharyngeal carcinoma treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for nasopharyngeal carcinoma treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The nasopharyngeal carcinoma treatment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
3. Nasopharyngeal Carcinoma Treatment Market Trends And Strategies
4. Nasopharyngeal Carcinoma Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Nasopharyngeal Carcinoma Treatment Growth Analysis And Strategic Analysis Framework
5.1. Global Nasopharyngeal Carcinoma Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Nasopharyngeal Carcinoma Treatment Market Growth Rate Analysis
5.4. Global Nasopharyngeal Carcinoma Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Nasopharyngeal Carcinoma Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Nasopharyngeal Carcinoma Treatment Total Addressable Market (TAM)
6.1. Global Nasopharyngeal Carcinoma Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Non-Keratinizing Undifferentiated Carcinoma
Non-Keratinizing Differentiated Carcinoma
Keratinizing Squamous Cell Carcinoma
6.2. Global Nasopharyngeal Carcinoma Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Ellence
Taxotere
Bleomycin
Methotrexate
6.3. Global Nasopharyngeal Carcinoma Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chemotherapy
Immunotherapy
Radiation Therapy
Other Therapies
6.4. Global Nasopharyngeal Carcinoma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
6.5. Global Nasopharyngeal Carcinoma Treatment Market, Sub-Segmentation Of Non-Keratinizing Undifferentiated Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Poorly Differentiated Type
Well-Differentiated Type
6.6. Global Nasopharyngeal Carcinoma Treatment Market, Sub-Segmentation Of Non-Keratinizing Differentiated Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Differentiated Type
6.7. Global Nasopharyngeal Carcinoma Treatment Market, Sub-Segmentation Of Keratinizing Squamous Cell Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Keratinizing Type
7. Nasopharyngeal Carcinoma Treatment Market Regional And Country Analysis
7.1. Global Nasopharyngeal Carcinoma Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Nasopharyngeal Carcinoma Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Nasopharyngeal Carcinoma Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Nasopharyngeal Carcinoma Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Nasopharyngeal Carcinoma Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Nasopharyngeal Carcinoma Treatment Market
9.1. China Nasopharyngeal Carcinoma Treatment Market Overview
9.2. China Nasopharyngeal Carcinoma Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Nasopharyngeal Carcinoma Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Nasopharyngeal Carcinoma Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Nasopharyngeal Carcinoma Treatment Market
10.1. India Nasopharyngeal Carcinoma Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Nasopharyngeal Carcinoma Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Nasopharyngeal Carcinoma Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Nasopharyngeal Carcinoma Treatment Market
11.1. Japan Nasopharyngeal Carcinoma Treatment Market Overview
11.2. Japan Nasopharyngeal Carcinoma Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Nasopharyngeal Carcinoma Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Nasopharyngeal Carcinoma Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Nasopharyngeal Carcinoma Treatment Market
12.1. Australia Nasopharyngeal Carcinoma Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Nasopharyngeal Carcinoma Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Nasopharyngeal Carcinoma Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Nasopharyngeal Carcinoma Treatment Market
13.1. Indonesia Nasopharyngeal Carcinoma Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Nasopharyngeal Carcinoma Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Nasopharyngeal Carcinoma Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Nasopharyngeal Carcinoma Treatment Market
14.1. South Korea Nasopharyngeal Carcinoma Treatment Market Overview
14.2. South Korea Nasopharyngeal Carcinoma Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Nasopharyngeal Carcinoma Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Nasopharyngeal Carcinoma Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Nasopharyngeal Carcinoma Treatment Market
15.1. Western Europe Nasopharyngeal Carcinoma Treatment Market Overview
15.2. Western Europe Nasopharyngeal Carcinoma Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Nasopharyngeal Carcinoma Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Nasopharyngeal Carcinoma Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Nasopharyngeal Carcinoma Treatment Market
16.1. UK Nasopharyngeal Carcinoma Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Nasopharyngeal Carcinoma Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Nasopharyngeal Carcinoma Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion